MAGIC Act

Summary

Market Access for Generic Insulin Competition or the MAGIC Act This bill provides a pathway for the Food and Drug Administration to approve chemically synthesized insulin or an analogue of chemically synthesized insulin as a generic drug under the abbreviated new drug application process.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 9 September 2019

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 9 September 2019

   Introduced

   Introduced in House

   Source: IntroReferral

3. 9 September 2019

   Introduced

   Introduced in House

   Source: IntroReferral

4. 10 September 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 9 September 2019 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 9 September 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 9 September 2019

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 9 September 2019

  Open at official source

Sponsors

• Rep. Kelly, Mike [R-PA-16] · R · Sponsor
• Scott Perry · R · Cosponsor
• Glenn Thompson · R · Cosponsor
• Rep. Fitzpatrick, Brian K. [R-PA-1] · R · Cosponsor
• Fred Keller · R · Cosponsor
• · hsif00 · Standing

Related records

No cross-record relationships stored yet.